Lykos Therapeutics develops investigational psychedelic compounds and provides therapist training programs to enhance treatment options for mental health conditions, particularly PTSD. By focusing on evidence-based research, the company aims to create safe and effective prescription psychedelic therapies that can be integrated into the healthcare system.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
HFounders
Product
Problem
Millions of Americans suffer from PTSD, yet treatment options remain limited, often failing to address the underlying neurobiological factors contributing to the condition. Current therapeutic approaches may not provide sufficient relief or address the emotional coping skills and self-experience deficits associated with PTSD.
Solution
Lykos Therapeutics is focused on developing investigational psychedelic compounds, specifically MDMA, combined with therapist training programs, to create prescription psychedelic therapies for mental health conditions, with an emphasis on PTSD. The company's approach involves rigorous, evidence-based research to ensure the safety and efficacy of its therapies, aiming for integration within the established healthcare system. Lykos is committed to working with the FDA to bring new treatment options to adults living with PTSD.
Target Audience
The primary target audience includes adults living with PTSD, mental health professionals, and healthcare systems seeking innovative and effective treatment options for PTSD.
Features
- Development of MDMA-assisted therapy for PTSD treatment.
- Therapist training programs designed to support psychedelic-assisted therapies.
- Focus on evidence-based research to validate safety and efficacy.
- Commitment to working with the FDA for therapy approval.
- Aim to improve emotional coping skills and self-experience in PTSD patients.